...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion
【24h】

Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion

机译：与外显子19缺失的非小细胞肺癌患者吉替尼对化疗的比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) afatinib as first-line treatment has been demonstrated to improve overall survival (OS) in patients with non-small cell lung cancer (NSCLC) harboring an exon 19 deletion (del19) of EGFR compared to platinum-doublet chemotherapy. However, it is unclear whether first-generation EGFR-TKIs improve OS in patients with del19 in the first-line treatment. Patients and Methods: We performed a post-hoc analysis of patients with del19 or L858R mutation of EGFR who received gefitinib in the NEJ002 study, which compared gefitinib to carboplatin-paclitaxel. Results: A total of 58 patients and 57 patients with del19 EGFR received gefitinib and carboplatin-paclitaxel, respectively. No OS differences were observed between patients receiving gefitinib and carboplatin-paclitaxel irrespective of del19 (29.3 months vs. 29.7 months, p= 0.53) or L858R (28.4 months vs. 25.1 months, p= 0.45). Conclusion: In contrast to afatinib, it is suggested that first-line gefitinib does not improve OS in patients with del19 of EGFR compared with platinum-doublet chemotherapy.
机译：背景：已证明第二代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）AFATINIB作为第一线治疗，以改善患有外显子19缺失的非小细胞肺癌（NSCLC）的患者的整体存活（OS） （Del19）EGFR与铂 - 双铂 - 双铂化疗相比。然而，目前尚不清楚第一代EGFR-TKI在德尔德患者中改善熟食术中的一线治疗。患者和方法：我们对NEJ002研究中接受吉替尼的EGFR患者进行了HOC患者的后HOC分析，将吉替尼对Carboplatin-PACLITAXEL进行了比较。结果：共有58名患者和57名德尔米特患者接受吉替尼和卡铂 - 紫杉醇。在接受吉替尼和卡铂 - 紫杉醇之间没有观察到OS差异，而不管Del19（29.3个月，第29.7个月，P = 0.53）或L858R（28.4个月与25.1个月，P = 0.45）。结论：与AFATINIB相比，建议，与铂 - 双峰化疗相比，第一线Gefitinib在EGFR的Del19患者中没有改善OS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号